Feasibility of abiraterone acetate treatment in patients with metastatic castration-resistant prostate cancer and atrial fibrillation

BACKGROUND: Abiraterone acetate (AA), a selective inhibitor of the CYP17 enzyme, demonstrated a significant improvement in the treatment of patients with metastatic castration-resistant prostate cancer. The risk of endocrine side effects, mainly an increased adrenal mineralocorticoid production, cou...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Prostate Int
मुख्य लेखकों: Rauch, Simon, Fong, Dominic, Morra, Elisa, Maines, Francesca, Caffo, Orazio, Spizzo, Gilbert
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Asian Pacific Prostate Society 2016
विषय:
Original Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4916059/
https://ncbi.nlm.nih.gov/pubmed/27358844
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.prnil.2016.02.002
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन